

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

MEI Pharma, Inc. (Name of Issuer)

Common Stock, \$0.00000002 par value (Title of Class of Securities)

572322402 **(CUSIP Number)**

Albert Cha 575 High St. #201 Palo Alto, CA 94301 (650) 688-0818

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

with copies to:

David J. Saul, Esq. Ropes & Gray LLP 1900 University Ave, 6th Floor East Palo Alto, CA 94303

June 11, 2013 (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of $\S\S240.13d-1(e)$, 240.13d-1(g), or 240.13d-1(g), check the following box. \square

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

1. NAM	NAME OF REPORTING PERSON.		
Vivo	Venture	s VII, LLC	
I.R.S.	. IDENT	TIFICATION NO. OF ABOVE PERSON: 27-4484686	
2. CHEC	CK THE	E APPROPRIATE BOX IF A MEMBER OF A GROUP	
(a) []	(b) []	
3. SEC 1	USE ON	VLY	
4. SOUI	RCE OF	FFUNDS	
00			
5. CHEC	CK BO	X IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS	2(d) OR 2(e) []
		IP OR PLACE OF ORGANIZATION	, , , , , , , , , , , , , , , , , , , ,
Delav	ware		
NUMBER OF	7.	SOLE VOTING POWER	0
SHARES			
BENEFICIALLY	8.	SHARED VOTING POWER	4,407,095 (1)
OWNED BY			
EACH	9.	SOLE DISPOSITIVE POWER	0
REPORTING			
PERSON	10.	SHARED DISPOSITIVE POWER	4,407,095 (1)
WITH			
		E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	7,095 (1)		
12. CHEC	CK BO	X IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	
[]			
13. PERC	CENT O	F CLASS REPRESENTED BY AMOUNT IN ROW (11)	25.13% (2)
14. TYPE	. TYPE OF REPORTING PERSON		
00	00		

⁽¹⁾ Includes 3,902,051 shares of common stock and warrants exercisable for an additional 411,041 shares held of record by Vivo Ventures Fund VII, L.P., and 85,044 shares of common stock and warrants exercisable for an additional 8,959 shares held of record by Vivo Ventures VII Affiliates Fund, L.P. Vivo Ventures VII, LLC is the sole general partner of both of the Vivo VII Funds and may be deemed to beneficially own such shares, and disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.

(2) Based upon 17,116,571 shares of common stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 9, 2013.

1. NAM	NAME OF REPORTING PERSON			
Vivo	Vivo Ventures Fund VII, L.P.			
I.R.S	S. IDEN	TIFICATION NO. OF ABOVE PERSON: 0001509160		
2. CHE	CK TH	E APPROPRIATE BOX IF A MEMBER OF A GROUP		
(a) [(b) []		
3. SEC	USE O	NLY		
	IRCE OI	F FUNDS		
00				
		X IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2	2(d) OR 2(e) []	
		IP OR PLACE OF ORGANIZATION		
	ware			
NUMBER OF	7.	SOLE VOTING POWER	0	
SHARES BENEFICIALLY	8.	SHARED VOTING POWER	4,313,092 (1)	
OWNED BY	0.	SHARED VOTING FOWER	4,513,092 (1)	
EACH	9.	SOLE DISPOSITIVE POWER	0	
REPORTING	٥.	0022 2:01 00:11 12 10 112.10	· ·	
PERSON WITH	10.	SHARED DISPOSITIVE POWER	4,313,092 (1)	
		TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	3,092 (1	<i>,</i>		
12. CHE	CCK BO	X IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
13. PER	CENT C	OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	24.61% (2)	
14. TYP	E OF RI	EPORTING PERSON		
PN				

⁽¹⁾ Includes 3,902,051 shares of common stock and warrants exercisable for an additional 411,041 shares.

⁽²⁾ Based upon 17,116,571 shares of common stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 9, 2013.

1. NAI	ME OF REPORTING PERSON		
Vivo	O Ventures VII Affiliates Fund, L.P.		
I.R.S	S. IDENTIFICATION NO. OF ABOVE PERSON: 0001538309		
2. CHI	ECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
(a)	[] (b) []		
3. SEC	USE ONLY		
4. SOU OO	JRCE OF FUNDS		
	ECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OF	R 2(e) []	
6. CIT	IZENSHIP OR PLACE OF ORGANIZATION		
Dela	aware		
NUMBER OF SHARES	7. SOLE VOTING POWER	0	
BENEFICIALLY OWNED BY	8. SHARED VOTING POWER	94,003 (1)	
EACH REPORTING	9. SOLE DISPOSITIVE POWER	0	
PERSON WITH	10. SHARED DISPOSITIVE POWER	94,003 (1)	
-	GREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 03 (1)		
12. CHE	ECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
13. PER	CENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	0.55% (2)	
14. TYF	14. TYPE OF REPORTING PERSON		
PN			

⁽¹⁾ Includes 85,044 shares of common stock and warrants exercisable for an additional 8,959 shares.

⁽²⁾ Based upon 17,116,571 shares of common stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 9, 2013.

1. NAM	NAME OF REPORTING PERSON.		
Vivo	Ventures V, LLC		
I.R.S	IDENTIFICATION NO. OF ABOVE PERSON: 84-1663511		
2. CHE	CK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		
(a) [] (b) []		
3. SEC	USE ONLY		
4. SOU	RCE OF FUNDS		
00			
5. CHE	CK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) O	R 2(e) []	
6. CITI	ZENSHIP OR PLACE OF ORGANIZATION		
Dela	ware		
NUMBER OF SHARES	7. SOLE VOTING POWER	0	
BENEFICIALLY OWNED BY	8. SHARED VOTING POWER	256,043 (1)	
EACH REPORTING	9. SOLE DISPOSITIVE POWER	0	
PERSON WITH	10. SHARED DISPOSITIVE POWER	256,043 (1)	
	REGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 43 (1)		
12. CHE	CK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
13. PERO	CENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	1.49% (2)	
14. TYPI	4. TYPE OF REPORTING PERSON		
00			

⁽¹⁾ Includes 229,268 shares of common stock and warrants exercisable for an additional 24,151 shares held of record by Vivo Ventures Fund V, L.P., and 2,374 shares of common stock and warrants exercisable for an additional 250 shares held of record by Vivo Ventures V Affiliates Fund, L.P. Vivo Ventures V, LLC is the sole general partner of both of the Vivo V Funds and may be deemed to beneficially own such shares, and disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.

(2) Based upon 17,116,571 shares of common stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 9, 2013.

1. NAM	NAME OF REPORTING PERSON.			
Vivo	Vivo Ventures Fund V, L.P.			
I.R.S	S. IDENT	TIFICATION NO. OF ABOVE PERSON: 20-2588981		
2. CHE	ECK THE	E APPROPRIATE BOX IF A MEMBER OF A GROUP		
(a) [[]	(b) []		
3. SEC	USE ON	NLY		
	JRCE OF	FUNDS		
00				
		X IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2	2(d) OR 2(e) []	
	_	IP OR PLACE OF ORGANIZATION		
	aware			
NUMBER OF	7.	SOLE VOTING POWER	0	
SHARES BENEFICIALLY	8.	SHARED VOTING POWER	253,419 (1)	
OWNED BY	0.	SHARED VOTING FOWER	255,419 (1)	
EACH	9.	SOLE DISPOSITIVE POWER	0	
REPORTING	٥.	0022 5:01 0011172 1 0 11211	· ·	
PERSON WITH	10.	SHARED DISPOSITIVE POWER	253,419 (1)	
	GREGAT 419 (1)	E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
12. CHE	ЕСК ВОХ	X IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES		
13. PER	CENT O	F CLASS REPRESENTED BY AMOUNT IN ROW (11)	1.48% (2)	
14. TYP	E OF RE	EPORTING PERSON		
PN				

⁽¹⁾ Includes 229,268 shares of common stock and warrants exercisable for an additional 24,151 shares.

⁽²⁾ Based upon 17,116,571 shares of common stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 9, 2013.

1. NAME OF REPORTING PERSON.	
Vivo Ventures V Affiliates Fund, L.P.	
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 20-3226166	
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	
(a) [] (b) []	
3. SEC USE ONLY	
4. SOURCE OF FUNDS	
00	
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURS	UANT TO ITEMS 2(d) OR 2(e) []
6. CITIZENSHIP OR PLACE OF ORGANIZATION	
Delaware	
NUMBER OF 7. SOLE VOTING POWER SHARES	0
BENEFICIALLY 8. SHARED VOTING POWER OWNED BY	2,624 (1)
EACH 9. SOLE DISPOSITIVE POWER REPORTING	0
PERSON 10. SHARED DISPOSITIVE POWER WITH	2,624 (1)
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERS 2,624 (1)	SON
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTA	IN SHARES
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	0.02% (2)
14. TYPE OF REPORTING PERSON PN	

⁽¹⁾ Includes 2,374 shares of common stock and warrants exercisable for an additional 250 shares.

⁽²⁾ Based upon 17,116,571 shares of common stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 9, 2013.

CUSIP No. 572322402

SCHEDULE 13D

Explanatory Note:

Item 1. Security and Issuer.

This Amendment No. 1 (the "Amendment") amends and supplements the statement on Schedule 13D filed on December 21, 2012 (the "Original 13D") by the Reporting Persons relates to the common stock, par value \$0.00000002 per share (the "Common Stock") of MEI Pharma, Inc., a Delaware corporation (the "Issuer"). The address of the principal executive offices of the Issuer is 11975 El Camino Real, Suite 101, San Diego, CA 92130.

Except as specifically provided herein, this Amendment does not modify any of the information previously reported on the Original 13D. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original 13D.

Item 4. Purpose of Transaction

Item 4 of the Statement is hereby amended to add the following:

The Reporting Persons sold 18,440 shares of Common Stock on May 16, 2013 and 250,000 shares of Common Stock on June 11, 2013.

Item 5. Interest in Securities of Issuer

This Amendment amends and restates Item 5 of the Original 13D in its entirety as set forth below:

- (a) The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Schedule 13D.
- (b) The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Schedule
- (c) Except as disclosed in Item 4, none of the Reporting Persons or their affiliates has effected any other transactions in the securities of the Issuer during the past 60 days.
- (d) Not Applicable.
- (e) Not Applicable.

Item 7. Materials to be Filed as Exhibits

Exhibit Joint Filing Agreement 99.1

Signature

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATED: June 13, 2013

Vivo Ventures VII, LLC

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures Fund VII, L.P.

By: Vivo Ventures VII, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures VII Affiliates Fund, L.P.

By: Vivo Ventures VII, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha

Title: Managing Member

Page 9 of 12

Vivo Ventures V, LLC

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures Fund V, L.P.

By: Vivo Ventures V, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures V Affiliates Fund, L.P.

By: Vivo Ventures V, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha

Title: Managing Member

Page 10 of 12

JOINT FILING AGREEMENT

In accordance with Rule 16a-3(j) and Rule 13d-1(k)(1) and under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of Schedules 13D and 13G (including any and all amendments thereto) with respect to the Common Stock, par value \$0.00000002 per share, of MEI Pharma, Inc. and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Forms Schedules 13D and l3G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; <u>provided</u> that no party is responsible for the completeness or accuracy of the information concerning any other filing party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.

In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of June 13, 2013.

Vivo Ventures VII, LLC

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures Fund VII, L.P.

By: Vivo Ventures VII, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures VII Affiliates Fund, L.P.

By: Vivo Ventures VII, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha
Title: Managing Member

Page 11 of 12

Vivo Ventures V, LLC

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures Fund V, L.P.

By: Vivo Ventures V, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures V Affiliates Fund, L.P.

By: Vivo Ventures V, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha

Title: Managing Member

Page 12 of 12